Atjaunināt sīkdatņu piekrišanu

E-grāmata: Current Applications of Pharmaceutical Biotechnology

  • Formāts - EPUB+DRM
  • Cena: 356,31 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

This book offers an authoritative review of biopharmaceuticals and their clinical relevance. Biopharmaceuticals have been showing high therapeutic potential by means of biological and biosimilar medicines, particularly for the treatment of cancer, chronic diseases (e.g. diabetes, Crohn's disease, psoriasis and rheumatoid arthritis), neurodegenerative disorders (e.g. multiple sclerosis), and they have also been contributing to the progress of innovative therapies such as assisted reproductive medicine. Since the eighties, several biopharmaceuticals have been approved and, due to patents expiration, many biosimilars are also marketed.

In this book, readers will find the most relevant updated information about the main clinical applications of pharmaceutical biotechnology. The authors provide expert analysis about the industrial challenges of recombinant proteins and the different classes of biopharmaceuticals, including monoclonal antibodies, vaccines, growth factors and stem cells. Topics such as bioprinting technologies in tissue engineering, gene therapy and personalized medicine are also covered in this book. Professionals, students and researchers interested in this field will find this work an important account.

Industrial Challenges of Recombinant Proteins
1(22)
Scott R. Rudge
Michael R. Ladisch
Insights on the Formulation of Recombinant Proteins
23(32)
Rita Ribeiro
Teresa Raquel Abreu
Ana Catarina Silva
Joao Goncalves
Joao Nuno Moreira
Therapeutic Antibody Engineering and Selection Strategies
55(32)
Joana Ministro
Ana Margarida Manuel
Joao Goncalves
Cytokines and Growth Factors
87(28)
A. C. Silva
J. M. Sousa Lobo
Hormones, Blood Products, and Therapeutic Enzymes
115(40)
Ana Catarina Silva
Ctedia Pina Costa
Hugo Almeida
Joao Nuno Moreira
Jose Manuel Sousa Lobo
Advances in Vaccines
155(34)
Helen H. Mao
Shoubai Chao
Human Pluripotent Stem Cells: Applications and Challenges for Regenerative Medicine and Disease Modeling
189(36)
Cldudia C. Miranda
Tiago G. Fernandes
M. Margarida Diogo
Joaquim M. S. Cabral
Addressing the Manufacturing Challenges of Cell-Based Therapies
225(54)
Miguel de Almeida Fuzeta
Andre Dargen de Matos Branco
Ana Femandes-Platzgummer
Cteudia Lobato da Silva
Joaquim M. S. Cabral
Bioprinting Technologies in Tissue Engineering
279(42)
Bengi Yilmaz
Aydin Tahmasebifar
Erkan Tiirker Baran
Gene Therapy
321(48)
Ana del Pozo-Rodriguez
Alicia Rodriguez-Gascon
Men Rodriguez-Castejon
Monica Vicente-Pascual
Itziar Gomez-Aguado
Luigi S. Battaglia
Maria Angeles Solinis
The Impact of Pharmacogenomics in Personalized Medicine
369(26)
Dev Bukhsh Singh
Index 395
Professor Ana Catarina Silva is an Assistant Professor of Pharmaceutical Technology and Biotechnology, and a Researcher at the Applied Molecular Biosciences Unit (UCIBIO) and UFP Energy, Environment and Health Research Unit (FP-ENAS), where she is currently developing lipid-based nanosystems to improve drug delivery and alternative systems to improve delivery of biopharmaceuticals. She has authored a number of scientific publications, and served as a referee for various international funding agencies. 

Professor Joćo Nuno Moreira is a group leader at the Center for Neuroscience and Cell Biology (CNC) and Assistant Professor with Habilitation (and Tenure) at the Faculty of Pharmacy, University of Coimbra, Portugal. His scientific work focuses on lipid-based nanosystems for targeted drug delivery and formulation of proteins. He is a co-author of several publications in peer-reviewed journals, 9 book chapters and 10 filed patents (3 of which have been grantedin the United States and 2 in Europe). 

Professor José Manuel Sousa Lobo is Head of the Laboratory of Pharmaceutical Technology and Executive Council Director of the FFUP. He is also President of the Portuguese Pharmacopoeia Commission. An expert on industrial pharmacy, he is responsible for Quality Overall Summaries for the EMA, and is an investigator at UCIBIO. 

Dr. Hugo Almeida holds a PhD in Pharmaceutical Sciences, and is Technical Director of a Medical Device company. He has authored numerous scientific publications, and his main research focuses on the application of stimuli-responsive polymers and lipid-based nanocarriers in ophthalmic drug delivery systems..